The beneficial role of vitamin D in Alzheimer's disease

American Journal of Alzheimer's Disease and other Dementias

Volumn 26, Issue 7, 2011, Pages 511-520

  Lu'O'Ng, Khanh Vinh Quôc ^a   Nguyên, Lan Thi Hoàng ^a  

^a Vietnamese American Medical Research Foundation   (United States)

Author keywords

Alzheimer's disease; calcitriol; dementia; vitamin D

Indexed keywords

APOLIPOPROTEIN E; CALCITRIOL; COLECALCIFEROL; CYCLOOXYGENASE 2; LIVER X RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NERVE GROWTH FACTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NITRIC OXIDE SYNTHASE; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROSTAGLANDIN; VITAMIN D; VITAMIN D RECEPTOR; VOLTAGE GATED CALCIUM CHANNEL;

ALZHEIMER DISEASE; COGNITION; COGNITIVE DEFECT; GENETIC ANALYSIS; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VITAMIN D DEFICIENCY;

EID: 84855239189     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317511429321     Document Type: Review

References (164)

1. Baker NL, Cook MN, Arrighi HM, Bullock R.. Hip fracture risk and subsequent mortality among Alzheimer's disease patients in the United Kingdom, 1988-2007. Age Ageing. 2011 ; 40 (1). 49-54
2. Sato Y, Asoh T, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in elderly women with Alzheimer's disease. Bone. 1998 ; 23 (6). 555-557 (Pubitemid 28529461)
3. Kipen E, Helme RD, Wark JD, Flicker L. Bone density, vitamin D nutrition, and parathyroid hormone levels in women with dementia. J Am Geriatr Soc. 1995 ; 43 (10). 1088-1091
4. Björkman MP, Sorva AJ, Tilvis RS. Does elevated parathyroid hormone concentration predict cognitive decline in older people?. Aging Clin Exp Res. 2010 ; 22 (2). 164-169
5. Sato Y, Kanoko T, Satoh K, Iwamoto J. Risk factors for hip fracture among elderly patients with Alzheimer's disease. J Neurol Sci. 2004 ; 223 (2). 107-112 (Pubitemid 39164351)
6. Watt F. Nuclear microscope analysis in Alzheimer's and Parkinson's disease: a review. Cell Mol Biol. 1996 ; 42 (1). 17-26
7. Murray FE, Landsberg JP, Williams RJ, Esiri MM, Watt F. Elemental analysis of neurofibrillary tangles in Alzheimer's disease using proton-induced X-ray analysis. Ciba Found Symp. 1992 ; 169: 201-210
8. McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosct Lett. 1987 ; 79 (1-2). 195-200 (Pubitemid 17144469)
9. Styren SD, Civin WH, Rogers J. Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's disease brain. Exp Neurol. 1990 ; 110 (1). 93-104 (Pubitemid 20376005)
10. Tooyama I, Kimura H, Akiyama H, McGeer PL. Reactive microglia express class I and class II antigens in Alzheimer's disease. Brain Res. 1990 ; 523 (2). 273-280 (Pubitemid 20230156)
11. Liew SCK, Penfold PL, Provis JM, Madigan MC, Billson FA. Modulation of MHC class II expression in the absence of lymphocytic infiltrates in Alzheimer's retinae. J Neurophathol Exp Neurol. 1994 ; 53 (2). 150-157 (Pubitemid 24081887)
12. Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging. 1988 ; 9 (4). 339-349 (Pubitemid 19262065)
13. Shalit F, Sregni B, Brodie C, Kott E, Huberman M. T lymphocyte subpopulations and activation markers correlate with severity of Alzheimer's disease. Clin Immunol Immunopathol. 1995 ; 75 (3). 246-250
14. Zota V, Nemirovsky A, Baron R, et al. HLA-DR alleles in amyloid β-peptide autoimmunity: a highly immunologic role for the DRB1*1501 allele. J Immunol. 2009 ; 183 (5). 3522-3530
15. Tokuda N, Levy RB. 1,25-hydroxyvitamin D3 stimulates phagocytosis but suppresses HLA-DR and CD13 antigen expression in human mononuclear phagocytes. Proc Soc Exp Biol Med. 1996 ; 211 (3). 244-250
16. Tokuda N, Mizuki N, Kasahara M, Levy RB. 1,25-hydroxyvitamin D3 down-regulation of HLA-DR on human peripheral blood monocytes. Immunol. 1992 ; 75 (2). 349-354
17. Takami K, Saitoh A, Kubota Y. 1,25-hydroxyvitamin D3 decreases the interon-gamma (IFN-gamma) induced HLA-DR expression but not intercellular adhesion molecule 1 (ICAM-1) on human keratinocytes. Reg Immunol. 1990-1991 ; 3 (5). 223-227
18. Tone T, Eto H, Katsuoka K, Nishioka K, Nishiyama S. Upexpression of gamma-interferon induced HLA-DR antigen expression on normal and transformed keratinocytes by 1,25 (OH) 2 vitamin D3 [in Japanese]. Nippon Hifuka Gakkai Zasshi. 1991 ; 101 (5). 519-525
19. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat. 2005 ; 29 (1). 21-30 (Pubitemid 39602785)
20. Sutherland MK, Somerville MJ, Yoong LKK, Bergeron C, Haussler MR, Mclachlan DRC. Reduction of vitamin D hormone receptor mRNA levels in Alzheimer as compared to Huntington hippocampus: correlation with calbindin-28 k mRNA levels. Mol Brain Res. 1992 ; 13 (3). 239-250
21. Gezen-Ak D, Dursun E, Ertan T, et al. Association between vitamin D receptor gene polymorphism and Alzheimer's disease. Tohoku J Exp Med. 2007 ; 212 (3). 275-282 (Pubitemid 47304994)
22. Luedecking-Zimmer E, DeKosky S, Nebes R, Kamboh I. Association of the 3'UTR transcription factor LBP-1c/CP2/LSF polymorphism with late-onset Alzheimer's disease. Am J Med Gene. 2003 ; 117B (1). 114-117 (Pubitemid 37059370)
23. Changaris DG, Keil LC, Severs WB. Angiotensin II immunohistochemistry of the rat brain. Neuroendocrinol. 1978 ; 25 (5). 257-274 (Pubitemid 8311742)
24. Healy DP, Printz MP. Distribution of immunoreactive angiotensin II, angiotensin I, angiotensinogen, and renin in the central nervous system of intact and nephrectomized rats. Hypertension. 1984 ; 6 (suppl 1). 130-136
25. Ganten D, Hermann K, Bayer D, Unger T, Lang RR. Angiotensin synthesis in the brain and increased turnover in hypertensive rats. Science. 1983 ; 221 (4613). 869-871 (Pubitemid 13034290)
26. Dzau VJ, Ingelfinger J, Pratt RE, Ellison KE. Identification of renin and angiotensinogen messenger RNA sequences in rat brain. Hypertension. 1986 ; 8 (6). 544-548 (Pubitemid 16037831)
27. Arregui A, Perry E, Rossor M, Tomlinson BE. Angiotensin converting enzyme in Alzheimer's disease: increased activity in caudate nucleus and cortical areas. J Neurochem. 1982 ; 38 (5). 1490-1492 (Pubitemid 12039305)
28. Barnes NM, Cheng CH, Costall B, Naylor RJ, Williams TJ, Wischik CM. Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease. Eur J Pharmacol. 1991 ; 200 (2-3). 289-292
29. Savaskan E, Hock C, Olivieri G, et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging. 2001 ; 22 (4). 541-546 (Pubitemid 32607737)
30. Akatsu H, Ogawa N, Kanesaka T, et al. High activity of peripheral blood angiotensin-converting enzyme is associated with later-onset of Alzheimer's disease. J Neurol Sci. 2011 ; 300 (1-2). 67-73
31. Hu J, Igarashi A, Kamata M, Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid β-peptide (Aβ); retards Aβ aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem. 2001 ; 276 (51). 47863-47868
32. Heming ML, Selkoe DJ. Amyloid β-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem. 2005 ; 280 (45). 37644-37650 (Pubitemid 41642372)
33. Hemming ML, Selkoe DJ, Farris W. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid β-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis. 2007 ; 26 (1). 273-281 (Pubitemid 46436503)
34. Zou K, Yamaguchi H, Akatsu H, et al. Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Aβ1-42) to Aβ1-40, and its inhibition enhances brain Aβ deposition. J Neurosci. 2007 ; 27 (32). 8628-8635 (Pubitemid 47254272)
35. Kölsch H, Jessen F, Freymann N, et al. ACE I/D polymorphism is a risk factor of Alzheimer's disease but not of vascular dementia. Neurosci Lett. 2005 ; 377 (1). 37-39 (Pubitemid 40255635)
36. Elkins JS, Douglas VC, Johnston SC. Alzheimer disease risk and genetic variation in ACE: a meta-analysis. Neurology. 2004 ; 62 (3). 363-368 (Pubitemid 38200844)
37. Lehmann DJ, Cortina-Borja M, Warden DR, et al. Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. Am J Epidemiol. 2005 ; 162 (4). 305-317 (Pubitemid 41389712)
38. Sleegers K, den Heijer T, van Dijk EJ, et al. ACE gene is associated with Alzheimer's disease and atrophy of hippocampus and amygdala. Neurobiol Aging. 2005 ; 26 (8). 1153-1159 (Pubitemid 40726007)
39. Lendon CL, Thaker U, Harris JM, et al. The angiotensin 1-converting enzyme insertion (I)/deletion (D) polymorphism does not influence the extent of amyloid or tau pathology in patients with sporadic Alzheimer's disease. Neurosci Lett. 2002 ; 328 (3). 314-318 (Pubitemid 34876673)
40. Pérez-Castrillón JL, Justo I, Sanz A, De Luis D, Dueñas A. Effect of angiotensin converting enzyme inhibitors on 1,25(OH)2 D levels of hypertensive patients. Relationship with ACE polymorphisms. Horm Metab Res. 2006 ; 38 (12). 812-816 (Pubitemid 46051502)
41. Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Phys Endocrinol Met. 2005 ; 288 (1). E125 - E132
42. Higiwara H, Furuhashi H, Nakaya K, Nakamura Y. Effects of vitamin D3 and related compounds on angiotensin converting activity of endothelial cells and on release of plasminogen activator from them. Chem Pharm Bull. 1988 ; 36 (12). 4858-4864 (Pubitemid 19048281)
43. Licastro F, Chiappelli M, Thal LJ, Masliah E. α-1-antichymotrypsin polymorphism in the gene promoter region affects survival and synapsis loss in Alzheimer's disease. Arch Gerontol Geriatr. 2004 ; (suppl 9). 243-251 (Pubitemid 38822874)
44. Lane RM, Farlow MR. Lipid homeostatis and apolipoprotein E in the development and progression of Alzheimer's disease. J Lipid Res. 2005 ; 46 (5). 949-968
45. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res. 2003 ; 118 (1-2). 140-146 (Pubitemid 37238996)
46. Thal DR, Papassotiropoulos A, Saido TC, et al. Capillary cerebral amyloid angiopathy identifies a distinct APOE 4-associated subtype of sporadic Alzheimer's disease. Acta Neuropathol. 2010 ; 120 (2). 169-183
47. Wolk DA, Dickkerson BC. the Alzheimer's disease neuroimaging initiative. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. PNAS. 2010 ; 107 (22). 10256-10261
48. Paz-y-Miño C, Carrera C, López-Cortés A, et al. Genetic polymorphisms in apolipoprotein E and glutathione peroxidase 1 genes in the ecuadorian population affected with Alzheimer's disease. Am J Med Sci. 2010 ; 340 (5). 373-377
49. Jouni ZE, McNamara DJ. Lipoprotein receptors of HL-60 macrophages. Effect of differentiation with tetramyristic phorbol acetate and 1,25-didroxyvitamin D3. Arterioscler Thromb. 1991 ; 11 (4). 995-1006
50. Husain K, Suarez E, Isidro A, Ferder L. Effects of paricalcitol and analapril on atherosclerotic injury in mouse aortas. Am J Nephrol. 2010 ; 32 (4). 296-304
51. Becker LE, Koleganova N, Piecha G, et al. Effects of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice. Am J Physiol Renal Physiol. 2011 ; 300 (3). F772 - F782
52. Ullrich C, Pirchl M, Humpel C. Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. Mol Cell Neurosci. 2010 ; 45 (4). 408-417
53. Buxbaum JD, Cullen EI, Friedhoff LT. Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. Front Biosci. 2002 ; 7: a50 - a59
54. Refolo LM, Malester B, LaFrancois J, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000 ; 7 (4). 321-331
55. Murphy S, Born E, Mathur SN, Field J. LXR/RXR activation enhances basolateral efflux of cholesterol in CaCo-2 cells. J Lipid Res. 2002 ; 43 (7). 1054-1064 (Pubitemid 34760876)
56. Sun Y, Yao J, Kim TW, Tall AR. Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J Biol Chem. 2003 ; 278 (30). 27688-27694 (Pubitemid 36899957)
57. Koldamova RP, Lefterov IM, Staufenbiel M, et al. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem. 2005 ; 280 (6). 4079-4088 (Pubitemid 40288571)
58. Jorde R, Figenschau Y, Hutchinson M, Emaus N, Grimnes G. High serum 25-hydroxyvitamin D concentrations are associated with a favorable serum lipid profile. Eur J Clin Nutr. 2010 ; 64 (12). 1457-1464
59. Karhapää P, Pihlajamäki J, Pörsti I, et al. Diverse associations of 25-hydroxyvitamin D and 1,25-dihydroxy-vitamin D with dyslipidaemias. J Intern Med. 2010 ; 268 (6). 604-610
60. Riek AE, Oh J, Bernal-Mizrachi C. Vitamin D regulates macrophage cholesterol metabolism in diabetes. J Steroid Biochem Mol Biol. 2010 ; 121 (1-2). 430-433
61. Gupta AK, Sexton RC, Rudney H. Effect of vitamin D3 derivatives on cholesterol synthesis and HMG-CoA reductase activity in cultured cells. J Lipid Res. 1989 ; 30 (3). 379-386 (Pubitemid 19082066)
62. Wang J-H, Keisala T, Salakivi T, Minasyan A, Kalueff AV, Tuohimaa P. Serum cholesterol and expression of ApoA1, LXRβ and SREBP2 in vitamin D receptor knock-out mice. J Steroid Biochem Mol Biol. 2009 ; 113 (3-5). 222-226
63. Jiang W, Miyamoto T, Kakizawa T, et al. Inhibition of LXRα signaling by vitamin D receptor: possible role of VDR in bile acid synthesis. Biochem Biophys Res Comm. 2006 ; 351 (1). 176-184 (Pubitemid 44635423)
64. Tashiro K, Ishii C, Ryoji M. Role of distal upstream sequence in vitamin D-induced expression of human CYP24 gene. Biochem Biophys Res Commun. 2007 ; 358 (1). 259-365
65. Jehan F, DeLuca HF. The mouse vitamin D receptor is mainly expressed through and Sp1-driven promoter in vivo. Arch Biochem Biophys. 2000 ; 377 (2). 273-283 (Pubitemid 30331888)
66. Chen HT, Chen JY, Huang YC, Chang HC, Hung WC. Function role of VDR in the activation of p27Kip1 by the VDR/Sp1 complex. J Cell Biochem. 2006 ; 98 (6). 1450-1456
67. Santpere G, Nieto M, Puig B, Ferrer I. Abnormal Sp1 transcription factor expression in Alzheimer disease and tauopathies. Neurosci Lett. 2006 ; 397 (1-2). 30-34 (Pubitemid 43340453)
68. Citron BA, Dennis JS, Zeitlin RS, Echeverria V. Transcription factor Sp1 dysregulation in Alzheimer's disease. J Neurosci Res. 2008 ; 86 (11). 2499-2506
69. Brock B, Basha R, DiPalma K, et al. Co-localization and distribution of cerebral APP and Sp1 and its relationship to amyloidogenesis. J Alzheimer's Dis. 2008 ; 13 (1). 71-80 (Pubitemid 351365624)
70. Christensen MA, Zhou W, Qing H, Lehman A, Philipsen S, Song W. Transcriptional regulation of BACE1, the β-amyloid precursor protein β-secretase, by Sp1. Mol Cell Biol. 2004 ; 24 (2). 865-874 (Pubitemid 38057936)
71. Docagne F, Gabriel C, Lebeurrier N, et al. Sp1 and Smad transcription factors co-operate to mediate TGF-β-dependent activation of amyloid-β precursor protein gene transcription. Biochem J. 2004 ; 383 (pt 2). 393-399 (Pubitemid 39446701)
72. Love S, Barber R, Wilcock GK. Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimers's disease. Brain. 1999 ; 122 (pt 2). 247-253 (Pubitemid 29067207)
73. Kassner SS, Bonaterra GA, Kaiser E, et al. Novel systemic markers for patients with Alzheimer disease?-A pilot study. Current Alzheimer Res. 2008 ; 5 (4). 358-366
74. Abeti R, Abramov AY, Duchen MR. β-amyloid activates PARP causing astrocytic metabolic failure and neuronal death. Brain. 2011 ; 134 (pt 6). 1658-1672
75. Infante J, Llorca J, Mateo I, et al. Interaction between Poly(ADP-Ribose) Polymerase 1 and Interleukin 1A genes is associated with Alzheimer's disease risk. Dement Geriatr Cogn Disord. 2007 ; 23 (4). 215-218 (Pubitemid 46496806)
76. Liu HP, Lin WY, Wu BT, et al. Evaluation of the poly(ADP-ribose) polymerase-1 gene variants in Alzheimer's disease. J Clin Lab Anal. 2010 ; 24 (3). 182-186
77. Bhatia M, Kirkland JB, Mecking-Gill KA. Modulation of poly(ADP-ribose) polymerase during neurophilic and monocytic differentiation of promyelocytic (NB4) and myelocytic (HL-60) leukaemia cells. Biochem J. 1995 ; 308 (pt 1). 131-137
78. Mabley JG, Wallace R, Pacher P, Murphy K, Szabó C. Inhibition of poly(ADP-ribose) polymerase-1 by the active form of vitamin D. Int J Mol Med. 2007 ; 19 (6). 947-952
79. Shen M, Yen A. Nicotinamide cooperates with retinoic acid and 1,25-dihydroxyvitamin D3 to regulate cell differentiation and cell cycle arrest of human myeloblastic leukemia cells. Oncology. 2009 ; 76 (2). 91-100
80. Moore M, Piazza A, Nolan Y, Lynch MA. Treatment with dexamethasone and vitamin D3 attenuates neuroinflammatory age-related changes in rat hippocampus. Synapse. 2007 ; 61 (10). 851-861 (Pubitemid 47328804)
81. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology. 1999 ; 53 (9). 1937-1942
82. Kroner Z. The relationship between Alzheimer's disease and diabetes: type 3 diabetes?. Altern Med Rev. 2009 ; 14 (4). 373-379
83. Takeda S, Sato N, Uchio-Yamada K, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A. 2010 ; 107 (15). 7036-7041
84. Fishel MA, Watson GS, Montine TJ, et al. Hyperinsulinemia provokes synchronous increases in central inflammation and β-amyloid in normal adults. Arch Neurol. 2005 ; 62 (10). 1539-1544 (Pubitemid 41434558)
85. de la Monte SM. Insulin resistance and Alzheimer's disease. BMB Reports. 2009 ; 42 (8). 475-481
86. Vanhanene M, Koivisto K, Moilanen L, et al. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology. 2006 ; 67 (5). 843-847 (Pubitemid 44394200)
87. Garcia-Lara JM, Aguilar-Navarro S, Gutiérrez-Robledo LM, Avila-Funes JA. The metabolic syndrome, diabetes, and Alzheimer's disease. Rev Invest Clin. 2010 ; 62 (4). 343-349
88. Pasinetti GM, Zhao Z, Qin W, et al. Caloric intake and Alzheimer's disease. Experimental approaches and therapeutic implications. Interdiscip Top Gerontol. 2007 ; 35: 159-175
89. Moroz N, Tong M, Longato L, Xu H, de la Monte SM. Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J Alzheimers Dis. 2008 ; 15 (1). 29-44
90. Ho AJ, Raji CA, Becker JT, et al. Cardiovascular Health Study; ADNI. Obesity is linked with lower brain volume in 700 AD and MCI patients. Neurobiol Aging. 2010 ; 31 (8). 1328-1339
91. Luchsinger JA, Cheng D, Tang MX, Schupf N, Mayeux R. Central obesity in the elderly is related to late-onset Alzheimer disease. Alzheimer Dis Assoc Disord. 2011 ;:
92. Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev. 2011 ; 12 (5). e426 - e437
93. Aksoy H, Akçay F, Kurtul N, Baykal O, Avci B. Serum 1,25 dihydroxyvitamin D (1,25(OH)2 D3). 25 hydroxyvitamin D (25(OHD) and parathormone levels in diabetic retinopathy. Clin Biochem. 2000 ; 33 (1). 47-51 (Pubitemid 30313043)
94. Kaur H, Donaghue KC, Chan AK, et al. Vitamin D deficiency is associated with retinopathy in children and aldolescents with type 1 diabetes. Diabetes Care. 2011 ; 34 (6). 1400-1402
95. Yiu YF, Chan YH, Yiu KH, et al. Vitamin D deficiency is associated with depletion of circulating endothelial progenitor cells and endothelial dysfunction in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011 ; 96 (5). E830 - E835
96. Verhaeghe J, Suiker AM, Van Bree R, et al. Increased clearance of 1,25(OH)2 D3 and tissue-specific responsiveness to 1,25(OH)2 D3 in diabetic rats. Am J Physiol. 1993 ; 265 (2 pt 1). E215 - E223
97. Chen S, Massaro JM, Fox CS, et al. Adiposity, cardiometabolic risk, and vitamin D status: the Framingham heart study. Diabetes. 2010 ; 59 (1). 242-248
98. Liel Y, Ulmer E, Shary J, Hollis BW, Bell NH. Low circulating vitamin D in obesity. Calcif Tissue Int. 1988 ; 43 (4). 199-201
99. Arunabh S, Pollack S, Yeh J, Aloia JF. Body fat content and 25-hydroxyvitamin D levels in healthy women. J Clin Endocrinol Metab. 2003 ; 88 (1). 157-161 (Pubitemid 36115158)
100. Blum M, Dolnikowski G, Seyoum E, et al. Vitamin D3 in fat tissue. Endocrine. 2008 ; 33 (1). 90-94
101. Evatt ML, DeLong MR, Khazai N, Triche S, Tangpricha V. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008 ; 65 (10). 1348-1352
102. Wilkins CH, Sheline YI, Roe CM, Birge SJ, Morris JC. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry. 2006 ; 14 (12). 1032-1040 (Pubitemid 44936995)
103. Oudshoorn C, Mattace-Raso FUS, van der Velde N, Colin EM, van der Cammen TJM. Higher serum vitamin D3 levels are associated with better cognitive test performance in patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2008 ; 25 (6). 539-543 (Pubitemid 351957417)
104. Llewellyn DJ, Lang IA, Langa KM, Melzer D. Vitamin D and cognitive impairment in the elderly U.S. population. J Gerontol A Biol Sci Med Sci. 2011 ; 66 (1). 59-65
105. Taghizadeh M, Djazayery A, Salami M, Eshraghian MR, Zavareh SA. Vitamin-D-free regimen intensifies the spatial learning deficit in Alzheimer's disease. Int J Neurosci. 2011 ; 121 (1). 16-24
106. Yu J, Gattoni-Celli M, Zhu H, et al. Vitamin D3-enriched diet correlated with a decrease of amyloid plaques in brain of AβPP transgenic mice. J Alzheimer Dis. 2011 ; 25 (2). 295-307
107. Landfield PW, Cadwallader-Neal L. Long-term treatment with calcitriol (1,25(OH)2 vit D3) retards a biomarker of hippocampal aging in rats. Neurobiol Aging. 1998 ; 19 (5). 469-477 (Pubitemid 29065496)
108. Klingner M, Apelt J, Kumar A, et al. Alterations in cholinergic and non-cholinergic neurotransmitter receptor densities in transgenic Tg2576 mouse brain with beta-amyloid plaque pathology. Int J Dev Neurosci. 2003 ; 21 (7). 357-369 (Pubitemid 37346400)
109. Heneka MT, Nadrigny F, Regen T, et al. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci U S A. 2010 ; 107 (13). 6058-6063
110. Kumar PT, Antony S, Nandhu MS, Sadanandan J, Naijil G, Paulose CS. Vitamin D3 restores altered cholinergic and insulin receptor expression in the cerebral cortex and muscarinic M3 receptor expression in pancreatic islets of streptozotocin induced diabetic rats. J Nutr Biochem. 2011 ; 22 (5). 418-425
111. Baski SN. Altered pressor response to norepinephrine in calcium- and vitamin D-deficient rats. Clin Exp Hypertens A. 1988 ; 10 (5). 811-832
112. De Novellis V, Loffreda A, Viagliano S, et al. Effects of dietary vitamin D deficiency on the cardiovascular system. Re Comm Chem Pathol Pharmacol. 1994 ; 83 (2). 125-144
113. Shimosawa T, Ando K, Fujita T. Enhancement of vasoconstrictor response by a noncacimic analogue of vitamin D3. Hypertension. 1993 ; 21 (2). 253-258 (Pubitemid 23035080)
114. Coon AL, Wallace DR, Mactutus CF, Booze RM. L-type calcium channels in the hippocampus and cerebellum of Alzheimer's disease brain tissue. Neurobiol Aging. 1999 ; 20 (6). 597-603 (Pubitemid 30064405)
115. Dursun E, Gezen-Ak D, Yilmazer S. A novel perspective for Alzheimer's disease: vitamin D receptor suppression by amyloid-β and preventing the amyloid-β induced alterations by vitamin D in cortical neurons. J Alzheimers Dis. 2011 ; 23 (2). 207-219
116. Brewer LD, Porter NM, Kerr DS, Landfield PW, Thibault O. Chronic 1α, 25-(OH)2 vitamin D3 treatment reduces Ca2+ -mediated hippocampal biomarkers of aging. Cell Calcium. 2006 ; 40 (3). 277-286 (Pubitemid 44087863)
117. Brewer LD, Thibault O, Chen KC, Langub MC, Landfield PW, Porter NM. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J Neurosci. 2001 ; 21 (1). 98-108 (Pubitemid 32098731)
118. Shan JJ, Li B, Taniguchi N, Pang PK. Inhibition of membrane L-type calcium channel activity and intracellular calcium concentration by 24R, 25-dihydroxyvitamin D3 in vascular smooth muscle. Steroids. 1996 ; 61 (11). 657-663 (Pubitemid 26379420)
119. Wu CK, Yeh HH. Nerve growth factor rapidly increases muscarinic tone in mouse medial septum/diagonal band of broca. J Neurosci. 2005 ; 25 (17). 4232-4242 (Pubitemid 40628767)
120. Poucet B, Herrmann T. Septum and medial frontal cortex contribution to spatial problem-solving. Behav Brain Res. 1990 ; 37 (3). 269-280 (Pubitemid 20111214)
121. Olton DS, Walker JA, Gage FH. Hippocampal connections and spatial discrimination. Brain Res. 1978 ; 139 (2). 295-308 (Pubitemid 8248257)
122. Calissano P, Matrone C, Amadoro G. Nerve growth factor as a paradigm of neurotrophins related to Alzheimer's disease. Develop Neurobiol. 2010 ; 70 (5). 372-383
123. Mobley WC, Neve RL, Prusiner SB, McKinley MP. Nerve growth factor increases mRNA levels for the prion protein and the β-amyloid protein precursor in developing hamster brain. Proc Natl Acad Sci U S A. 1998 ; 85 (24). 9811-9815
124. Araki W, Wurtman RJ. Increased expression of amyloid precursor protein and amyloid precursor-like protein 2 during trophic factor withdrawal-induced death of neuronal PC12 cells. Brain Res Mol Brain Res. 1998 ; 56 (1-2). 169-177 (Pubitemid 28271673)
125. De Rosa R, Garcia AA, Braschi C, et al. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci U S A. 2005 ; 102 (10). 3811-3816 (Pubitemid 40360709)
126. Tuszynski MH, Thal L, Pay M, et al. A phase I clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005 ; 11 (5). 551-555 (Pubitemid 40691288)
127. Féron F, Burne THJ, Brown J, et al. Developmental vitamin D3 deficiency alters the adult rat brain. Brain Res Bull. 2005 ; 65 (2). 141-148 (Pubitemid 40348799)
128. Cornet A, Baudet C, Neveu I, Baron-Van Evercooren A, Brachet P, Naveilhan P. 1,25-dihydroxyvitamin D3 regulates the expression of VDR and NGF gene in Schwann cells in vitro. J Neurosci Res. 1998 ; 53 (6). 742-746 (Pubitemid 28423881)
129. Musiol IM, Feldman D. 1,25-dihydroxyvitamin D3 induction of nerve growth factor in L929 mouse fibroblasts: effect of vitamin D receptor regulation and potency of vitamin D3 analogs. Endocrinology. 1997 ; 138 (1). 12-18 (Pubitemid 27009399)
130. Veenstra TD, Fahnestock M, Kumar R. An AP-1 site in the nerve growth factor promoter is essential for 1,25-dihydroxyvitamin D3 -mediated nerve growth factor expression in osteoblasts. Biochemistry. 1998 ; 37 (17). 5988-5994 (Pubitemid 28196753)
131. Ricciotti E, Fitzgerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011 ; 31 (5). 986-1000
132. Wanatabe Y, Hamada K, Bommelaer-Bayt MC, et al. Distinct localization of prostaglandin D2, E2, and F2α binding sites in monkey brain. Brain Res. 1989 ; 478 (1). 142-148
133. Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci U S A. 1996 ; 93 (6). 2317-2321 (Pubitemid 26104347)
134. Yasojima K, Schwab C, McGeer EG, McGeer PL. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNA and proteins in human brain and peripheral organs. Brain Res. 1999 ; 830 (2). 226-236 (Pubitemid 29297950)
135. Ho L, Pieroni L, Winger D, Purohit DP, Aisen PS, Pasinetti GM. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J Neurosci Res. 1999 ; 57 (3). 295-303 (Pubitemid 29339785)
136. Xiang Z, Ho L, Yemul S, et al. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expr. 2002 ; 10 (5-6). 271-278 (Pubitemid 35315389)
137. Qin W, Ho L, Pompl PN, et al. Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity. J Biol Chem. 2003 ; 278 (51). 50970-50977 (Pubitemid 38020330)
138. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. 1995 ; 45 (1). 51-55
139. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease; a review of 17 epidemiologic studies. Neurology. 1996 ; 47 (2). 425-432 (Pubitemid 26324038)
140. Moreno J, Krishnan AV, Swami S, et al. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. 2005 ; 65 (17). 7917-7925 (Pubitemid 41297270)
141. Apama R, Subhashini J, Roy KR, et al. Selective inhibition of cyclooxygenase-2 (COX-2) by 1alpha,25-dihydroxy-16-ene-23-yne-vitamin D3, a less calcemic vitamin D analog. J Cell Biochem. 2008 ; 104 (5). 1832-1842
142. Bains JS, Shaw CA. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Rev. 1997 ; 25 (3). 335-358 (Pubitemid 28071452)
143. Butterfield DA, Howard B, Yatin S, et al. Elevated oxidative stress in models of normal brain aging and Alzheimer's disease. Life Sci. 1999 ; 65 (18-19). 1883-1892 (Pubitemid 29506923)
144. de la Monte SM, Ganju N, Feroz N, et al. Oxygen free radical injury is sufficient to cause some Alzheimer-type molecular abnormalities in human CNS neuronal cells. J Alzheimers Dis. 2000 ; 2 (3-4). 261-281 (Pubitemid 32095611)
145. Zemlan FP, Thienhaus OJ, Bosmann HB. Superoxide dismutase activity in Alzheimer's disease: possible mechanism for paired helical filament formation. Brain Res. 1989 ; 476 (1). 160-162 (Pubitemid 19006378)
146. Tesco G, Latorraca S, Piersanti P, Sorbi S, Piacentii S, Amaducci L. Free radical injury in skin cultured fibroblasts from Alzheimer's disease patients. Ann NY Acad Sci. 1992 ; 26: 49-153
147. Cohen MS, Mesler DE, Snipes RG, Gray TK.. 1,25-dihydroxyvitamin D3 activates secretion of hydrogen peroxide by human monocytes. J Immunol. 1986 ; 136 (3). 1049-1053 (Pubitemid 16146396)
148. Sun X, Zemel MB.. 1α,25-dihydroxyvitamin D3 modulation of adipocyte reactive oxygen species production. Obesity. 2007 ; 15 (8). 1944-1953 (Pubitemid 47402226)
149. Levy R, Malech HL. Effect of 1,25-dihydroxyvitamin D3, lipopolysaccharide, or lipoteichoic acid on the expression of NADPH oxidase components in cultured human monocytes. J Immunol. 1991 ; 147 (9). 3066-3071
150. Bao BY, Ting HJ, Hsu JW, Lee YF. Protective role of 1α,25- dihydroxyvitamin D3 against oxidative stress in nonmalignant human prostate epithelial cells. Int J Cancer. 2008 ; 122 (12). 2699-2706
151. Somjen D, Katzburg S, Grafi-Cohen M, Knoll E, Sharon O, Posner GH. Vitamin D metabolites and analogs induce lipoxygenase mRNA expression and as well as reactive oxygen species (ROS) production in human bone cell line. J Steroid Biochem Mol Biol. 2011 ; 123 (1-2). 85-89
152. Sardar S, Chakraborty A, Chatterjee M. Comparative effectiveness of vitamin D3 and dietary vitamin E on peroxidation of lipids and enzymes of the hepatic antioxidant system in Sprague-Dawley rats. Int J Vitam Nutr Res. 1996 ; 66 (1). 39-45
153. Schuman EM, Madison DV. A requirement for the intercellular messenger nitric oxide in long-term potentiation. Science. 1991 ; 254 (5037). 1503-1506 (Pubitemid 21917489)
154. Zorumski CF, Izumi Y. Nitric oxide and hippocampal synaptic plasticity. Biochem Pharmacol. 1993 ; 46 (5). 777-785 (Pubitemid 23272756)
155. De Servi B, La Porta CAM, Bontempelli M, Comolli R. Decrease of TGF-β1 plasma levels and increase of nitric oxide synthase activity in leukocytes as potential biomarkers of Alzheimer's disease. Exper Gerontol. 2002 ; 37 (6). 813-821 (Pubitemid 34518499)
156. Dorheim MA, Tracey WR, Pollock JS, Grammas P. Nitric oxide synthase activity is elevated in brain microvessels in Alzheimer's disease. Biochem Biophys Res Commun. 1994 ; 205 (1). 659-665 (Pubitemid 24381677)
157. Lüth HJ, Holzer M, Gärtner U, Staufenbiel M, Arendt T. Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology. Brain Res. 2001 ; 913 (1). 57-67 (Pubitemid 32786931)
158. Nathan C, Calingasan N, Nezezon J, et al. Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J Exp Med. 2005 ; 202 (9). 1163-1169 (Pubitemid 41586946)
159. Chang JM, Kuo MC. Kuo HT, et al. 1α,25-dihydroxyvitamin D3 regulates inducible nitric oxide synthase messenger RNA expression and nitric oxide release in macrophage-like RAW 264.7 cells. J Lab Clin Med. 2004 ; 143 (1). 14-22
160. Garcion E, Nataf S, Berod A, Darcy F. Brachet P. 1,25-dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. Brain Res Mol Brain Res. 1997 ; 45 (2). 255-267 (Pubitemid 27170702)
161. Equils O, Naiki Y. Shapiro AM, et al. 1,25-dihydroxyvitamin D3 inhibits lipopolysaccharide-induced immune activation in human endothelial cells. Clin Exper Immunol. 2005 ; 143 (1). 58-64
162. Garcion E, Sindji L, Leblondel G, Brachet P. Darcy F. 1,25-dihydroxyvitamin D3 regulates the synthesis of γ-glutamyl transpeptidase and glutathione levels in rat primary astrocytes. J Neurochem. 1999 ; 73 (2). 859-866 (Pubitemid 29339862)
163. Bell NH, Shaw S, Turner RT. Evidence that 1,25-dihydroxyvitamin D3 inhibits the hepatic production of 25-hydroxyvitamin D in man. J Clin Invest. 1984 ; 74 (4). 1540-1544 (Pubitemid 15200250)
164. Luong VQK, Nguyen THL. Coexisting hyperparathyroidism and primary hyperparathyroidism with vitamin D-deficient osteomalacia in a Vietnamese immigrant. Endocr Pract. 1996 ; 2 (4). 250-254